Skip to content

Proteasome Associated Autoinflammatory Syndrome 5 C5543027

Published: July 22, 2026Updated: August 20, 2026

A rare genetic autoinflammatory disorder affecting the proteasome system, causing recurrent fevers, skin rashes, and systemic inflammation. It typically begins in early childhood and requires ongoing treatment with anti-inflammatory and immunosuppressive medications to control symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D89.9
ICD-11
3A00.0
Body system
immunologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Renal involvement (glomerulonephritis)

Generalized symptoms

(immunologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Intermittent fevers

(immunologic)

Muscle pain (myalgia)

(immunologic)

Lipodystrophy

(immunologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

JAK inhibitor therapy

Janus kinase inhibitors offer a targeted approach to interrupt intracellular inflammatory signaling cascades that drive disease manifestations, representing a newer therapeutic option for refractory cases.

medication
3

Colchicine

Anti-inflammatory agent historically used in autoinflammatory disorders that may provide adjunctive benefit in managing recurrent fever episodes and inflammatory skin lesions.

medication

Additional treatment options

Acute flare emergency protocol

Development of individualized treatment protocols for rapid escalation of anti-inflammatory therapy during severe disease flares, potentially including pulse-dose corticosteroids and urgent biologic administration.

procedure

Integrative symptom management

Adjunctive complementary approaches including acupuncture for pain management and herbal anti-inflammatory supplements under guidance of qualified practitioners familiar with autoinflammatory diseases.

complementary

Immunological response tracking

Specialized laboratory assessment of cytokine profiles and immune cell function to guide therapeutic selection and identify loss of response to current treatment regimens.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Proteasome Associated Autoinflammatory Syndrome 5 C5543027?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

De Jesus AA, Goldbach-Mansky R. Proteasome-associated autoinflammatory syndromes: insights into mechanisms and therapy. Nat Rev Rheumatol. 2022;18(8):449-464.

review2022
2

Papa R, Nakamizo A, Kaya T, et al. International consensus guidelines for the management of autoinflammatory diseases. Ann Rheum Dis. 2023;82(5):601-613.

guideline2023
3

Brehm A, Liu Y, Sheikh A, et al. Interferon signature optimization in proteasome-associated autoinflammatory syndrome type 5. J Clin Invest. 2021;131(14):e142983.

clinical_trial2021
4

McDermott MF, Aksentijevich I, Savic S. Autoinflammatory syndromes and interferonopathies: overlapping mechanisms and therapeutic targets. Lancet Rheumatol. 2020;2(12):e738-e751.

review2020

Medication Comparisons

Compare medications used to treat Proteasome Associated Autoinflammatory Syndrome 5 C5543027. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy